In a research note issued to investors, Michael Higgins at Roth Capital Reiterated their Buy rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). The analyst placed a $7.50 price target on the stock which indicates a 83.82% upside to the last closing price. In the year following Higgins’s ratings, the stocks covered yield an average return of 1.50% according to TipRanks.com. In the past year 5 out of 14 recommendations or 36.00% were successful.
In looking at the consensus numbers, the sell-side analysts covering the stock have a mean target price of $6.5 for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). This number is the mean estimate from the 6 research brokerages that recently issued reports on the firm.
According to Wall Street, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is expected to report earnings per share for the current fiscal quarter of $-0.26. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.27.
The average recommendation is the arithmetical average of the individual analyst ratings contributed by sell-side research to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 represents a Strong Buy and 5 represents a Strong Sell, has the equity is ranked 2.57 based on 6 broker recommendations. Of the 6 analyst estimates, the most bullish sees the stock reaching $14 within the next 12 months while the most bearish analyst sees the stock at $3 within the year.
Taking a look at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company’s products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.
